Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02818023
Title Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Pittsburgh
Indications

mucosal melanoma

skin melanoma

melanoma

Therapies

Cobimetinib + Pembrolizumab + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST